There are many possible reasons why a drug may require modified or targeted release. Some of these are related to the characteristics of the product itself, such as its pharmacodynamic or pharmacokinetic profile and the need to avoid degradation in specific areas of the gastrointestinal tract, or a desire to manage a product’s life cycle in the market. Others arise from clinical considerations like the importance of taking a drug to the precise site in the gut where release will be most effective, or improving patient compliance.
At Quay Pharma we have world-leading expertise in the science of modified release technologies, and a wealth of experience covering a wide range of modified and targeted release projects. We can provide you with a vast range of options to modify the rate at which an API is released, and for ensuring that it is delivered only to a specific, predetermined site within the gastrointestinal tract. All of the formulations we develop are provided to clients with full Intellectual Property rights, and on a royalty-free basis. Our work is always and only carried out on a fee-for-service basis.